معرفی
Noël JM Raynal is an Associate Professor in the Department of Pharmacology and Physiology at the University of Montreal's Faculty of Medicine and a Principal Investigator at the Azrieli Research Center at CHU Sainte-Justine. He serves as Director of the Chemical Molecule Screening Platform at the research center. Dr. Raynal leads a research laboratory focused on epigenetic pharmacology of cancer and drug discovery through molecular screening systems.
Dr. Raynal's research expertise lies in developing 3D cell culture models that better reproduce cancers in the laboratory, which his team characterizes at epigenetic and pharmacological levels. His laboratory focuses on both pediatric cancers (including leukemia, neuroblastoma, and sarcomas) and adult cancers (such as lung cancer and triple-negative breast cancer). His work combines epigenetic drugs targeting DNA methylation and histone modifications with other therapeutic approaches to identify synergistic anticancer interactions.
Analysis of Dr. Raynal's recent publications reveals a strong focus on drug repurposing strategies, particularly applying existing medications to new cancer indications. His research demonstrates expertise in epigenetic mechanisms including DNA methylation, histone acetylation, and CDK9 inhibition, with applications across multiple cancer types. A notable trend is his laboratory's work on translating basic epigenetic discoveries into potential therapeutic applications, particularly for difficult-to-treat pediatric malignancies.
Scientific Awards:
- Bourse de chercheur-boursier Senior du FRQS (2024-2028)
- Bourse de chercheur-boursier Junior 2 du FRQS (2020-2024)
- Bourse IRICOR-ONCOPOLE pour l'Entreprenariat en Sciences de la Vie (2020-2021)
- Bourse de chercheur-boursier Junior 1 du FRQS (2016-2020)
- CIHR-New Principal Investigator Award (2015)
- Bourse de transition, Fondation Cole (2013-2016)
Dr. Raynal has successfully mentored numerous graduate students and postdoctoral fellows who have contributed to his research program. His laboratory has secured substantial grant funding from multiple sources including FRQS and CIHR, supporting innovative research in epigenetic pharmacology. Dr. Raynal collaborates extensively with clinicians and researchers at CHU Sainte-Justine and other institutions to translate basic discoveries into potential therapeutic applications.
His laboratory at the Azrieli Research Center at CHU Sainte-Justine includes master's students, postdoctoral fellows, and research assistants working together on various aspects of cancer epigenetics and drug discovery. The team utilizes advanced molecular screening systems and 3D cell culture models to investigate cancer biology and identify promising therapeutic approaches.
